Mother always said, “You can lead a horse to free data but you can’t make him analyze it.” A recent study by the editors of The Journal of the American Medical Association revealed that few academic institutions and small biopharma firms make use of clinical trial data made available by large pharmaceutical companies. The Journal noted that, while centralized databases are bringing together more and more results from a wide variety of clinical trials, analyzing existing data in new and different ways can be costly. Further, data gathered for one purpose might not meet the endpoints of subsequent studies. These results may lead some to reassess the value of the initiative against the administrative and I.T. costs of participation.